Songtao Li

Songtao Li

Auto-generated profile, based on publicly available information

Songtao Li

Traditional Chinese Medicine (TCM) Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 611137, PR China; Clinical School of Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, PR China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2023 in Acta Biomaterialia
Verified
Journal Article
Closed access
SLSongtao Li
Songtao Li
XMXiangrui Meng
Xiangrui Meng
BPBo Peng
Bo Peng
JHJu Huang
Ju Huang
JLJingwen Liu
Jingwen Liu
TTtangjy tang
tangjy tang

17 June 2024 in Biomaterials
Verified
Journal Article
Open access
HXHang Xiao
Hang Xiao
XMXiangrui Meng
Xiangrui Meng
SLSongtao Li
Songtao Li
ZLZhiyong Li
Zhiyong Li
SFShuo Fang
Shuo Fang
LMLi Ma
Li Ma
After orthopedic surgeries, such as hip replacement, many patients are prone to developing deep vein thrombosis (DVT), which in severe cases can lead to fatal pulmonary embolism or major bleeding. Clinical intervention with high-dose anticoagulant therapy inevitably carries the risk of bleeding. Therefore, a targeted drug delivery system that adjusts local DVT lesions and potentially reduces drug dosage and toxic side effects important. In this study, we developed a targeted drug delivery platelet-derived nanoplatform (AMSNP@PM-rH/A) for DVT treatment that can simultaneously deliver a direct thrombin inhibitor (DTI) Recombinant Hirudin (rH), and the Factor Xa inhibitor Apixaban (A) by utilizing Aminated mesoporous silica nanoparticles (AMSNP). This formulation exhibits improved biocompatibility and blood half-life and can effectively eliminate deep vein thrombosis lesions and achieve therapeutic effects at half the dosage. Furthermore, we employed various visualization techniques to capture the targeted accumulation and release of a platelet membrane (PM) coating in deep vein thrombosis and explored its potential targeting mechanism.